Alnylam’s innovative approach, particularly with its RNA interference therapeutic, mivelsiran, is nearing additional Phase 1 data, which could position the company favorably in the competitive l ...

(NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-9 reverse share split ...

After hours: November 29 at 4:06 PM EST Loading Chart for RNA ...

Universal rRNA depletion can put the power of RNA-seq at the disposal of researchers studying any organism, from dangerous pathogens to vital plant crops. The RNA sequencing (RNA-seq) revolution ...

Here, the authors generated an RSV preF self-amplifying RNA vaccine and show that a single dose induces potent innate, cellular, and humoral immunity in RSV-infected in naïve and pre-exposed non ...

and a licensing deal with China’s Shanghai Argo Biopharmaceutical covering two RNAi interference (RNAi) therapies in the cardiovascular and metabolic diseases area. Aficamten is a would-be ...

Novartis also announced another agreement as JPM got underway, namely a licensing deal with China’s Shanghai Argo Biopharmaceutical covering two RNAi interference (RNAi) therapies in the ...